Literature DB >> 2285633

Atenolol in dilated cardiomyopathy: a clinical instrumental study.

A V Mattioli1, M G Modena, G Fantini, G Mattioli.   

Abstract

The usefulness of beta blockers in the treatment of congestive heart failure has been questioned. We selected 11 patients, mean age 47.1 +/- 13.8, affected by dilated cardiomyopathy in NYHA class III, who had been taking digoxin and diuretics for a long time. Atenolol 50 mg was added to conventional therapy. Both before and 3 months after treatment a clinical evaluation, chest x-ray, an exercise test, and an echocardiogram were performed. We observed an improvement of NYHA class in five patients. However, the exercise test showed no improvement: 2310 +/- 1299 vs. 2902 +/- 983 total kgm (ns). The echocardiogram showed improvements of the end-systolic diameter (from 6.3 +/- 1 cm to 5.9 +/- 0.8 cm; p less than 0.02), the fractional shortening (from 13.6 +/- 6.3% to 15.2 +/- 5.6%; p less than 0.05) the radius/thickness ratio (from 4.14 +/- 0.5 to 3.5 +/- 0.5; p less than 0.05), and the wall stress (from 208.4 +/- 49 g/cm2 to 163.5 +/- 41 g/cm2; p less than 0.02). The inotropic state index did not show any changes. We conclude that in some patients with dilated cardiomyopathy beta blockers may improve the clinical status and left ventricular performance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2285633     DOI: 10.1007/bf01857761

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  16 in total

1.  Mechanism of norepinephrine depletion in experimental heart failure produced by aortic constriction in the guinea pig.

Authors:  J F Spann; C A Chidsey; P E Pool; E Braunwald
Journal:  Circ Res       Date:  1965-10       Impact factor: 17.367

Review 2.  Neurohormonal interactions and adaptations in congestive heart failure.

Authors:  M Packer
Journal:  Circulation       Date:  1988-04       Impact factor: 29.690

Review 3.  Are beta-adrenergic-blocking drugs useful in the treatment of dilated cardiomyopathy?

Authors:  J Alderman; W Grossman
Journal:  Circulation       Date:  1985-05       Impact factor: 29.690

4.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

Authors:  M R Bristow; R Ginsburg; V Umans; M Fowler; W Minobe; R Rasmussen; P Zera; R Menlove; P Shah; S Jamieson
Journal:  Circ Res       Date:  1986-09       Impact factor: 17.367

5.  Alterations in left ventricular relaxation and diastolic compliance in congestive cardiomyopathy.

Authors:  W Grossman; L P McLaurin; E L Rolett
Journal:  Cardiovasc Res       Date:  1979-09       Impact factor: 10.787

6.  Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response.

Authors:  M B Fowler; J A Laser; G L Hopkins; W Minobe; M R Bristow
Journal:  Circulation       Date:  1986-12       Impact factor: 29.690

7.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.

Authors:  F Waagstein; A Hjalmarson; E Varnauskas; I Wallentin
Journal:  Br Heart J       Date:  1975-10

8.  Elimination of exercise-induced regional myocardial dysfunction by a bradycardiac agent in dogs with chronic coronary stenosis.

Authors:  B D Guth; G Heusch; R Seitelberger; J Ross
Journal:  Circulation       Date:  1987-03       Impact factor: 29.690

9.  Beta-blockers in dilated cardiomyopathies: they work.

Authors:  F Waagstein; A Hjalmarson; K Swedeberg; I Wallentin
Journal:  Eur Heart J       Date:  1983-01       Impact factor: 29.983

10.  Beneficial effects of long-term beta-blockade in congestive cardiomyopathy.

Authors:  K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal:  Br Heart J       Date:  1980-08
View more
  3 in total

Review 1.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure.

Authors:  Valerio Zacà; Sharad Rastogi; Sudhish Mishra; Mengjun Wang; Victor G Sharov; Ramesh C Gupta; Sidney Goldstein; Hani N Sabbah
Journal:  Cardiology       Date:  2008-10-02       Impact factor: 1.869

3.  β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure.

Authors:  Jarmila Machackova; Santosh K Sanganalmath; Vijayan Elimban; Naranjan S Dhalla
Journal:  J Cell Mol Med       Date:  2011-03       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.